Back To Resources
    Subscribe to PCE Communications
    Choose Your Subscription

    Healthcare Q4 2022

    Q4 2022 Healthcare

    Industry Trends

    Healthcare Acquisitions Drop in 2022

    The healthcare industry’s deal volume fell by 30% in 2022 to 2,878 transactions, and aggregate deal value declined 56% to $202 billion, according to a report by S&P Global Market Intelligence. The decline is partly attributable to an imbalance in expectations as healthcare executives have been hesitant to accept lower valuations amid significant market declines. In contrast, acquirers have seen record-high 2021 valuations as ceilings, not a baseline to begin negotiation.1 2

    Private Equity Firms Continue Roll-up of Healthcare Companies

    Private equity firms have increased healthcare services acquisitions over the last couple of years as they continue rolling-up companies in the sector, according to data from Pitchbook. PE firms have completed over 725 healthcare services acquisitions by the third quarter, 77% of which are add-ons. Volume surpassed 2020 levels, although falling short of 2021’s high. With looming recession concerns, PE firms are expected to remain acquisitive as healthcare services are typically considered more resilient.3

    Hospitals Continue to Face Inflation and Tight Labor Markets in 2023

    Hospitals faced a challenging year as inflation and labor shortages tightened margins, a trend expected to continue into 2023, according to a report from Deloitte. Affordability issues for patients and continuing supply-chain constraints will likely hamper the industry’s outlook. Payers, who have not yet fully felt the impact of inflation, are also expected to face rising prices as fixed-rate contracts are renegotiated over the coming years.4

    J&J Acquire Heart-Device Maker Abiomed for $16.6 Billion

    In December, Johnson & Johnson (J&J) completed one of the year’s largest acquisitions with their purchase of heart-device maker Abiomed Inc. for $16.6 billion. The transaction was an all-cash offer at $380 per share, in addition to shareholders receiving a non-tradeable contingent value-right, worth up to $35 per share if certain commercial and clinical milestones are met. The company will operate as a standalone business under J&J’s MedTech segment.5

    Largest Transactions Closed

    • Target
    • Buyer
    • Value($mm)
    • Abiomed, Inc.
    • Johnson & Johnson
    • $18,976.96
    • Change Healthcare Inc.
    • Optum, Inc.
    • $13,685.27
    • Biohaven Pharmaceutical Holding Company Ltd.
    • Pfizer Inc.
    • $12,184.48
    • Global Blood Therapeutics, Inc.
    • Pfizer Inc.
    • $5,881.63
    • ChemoCentryx, Inc.
    • Amgen Inc. 
    • $3,972.23
    • Covetrus, Inc.
    • Clayton, Dubilier & Rice, LLC; TPG Capital, L.P.; TPG Global, LLC
    • $3,558.21
    • Biosimilars Portfolio and Related Commercial and Operational Capabilities of Viatris Inc.
    • Biocon Biologics Limited
    • $3,285.00
    • Hanger, Inc.
    • Patient Square Capital, LP
    • $1,397.67
    • Shields Specialty Pharmacy Holdings, LLC
    • Walgreens Boots Alliance, Inc.
    • $1,370.00
    • Magellan Rx Management, LLC
    • Prime Therapeutics, LLC
    • $1,350.00

    Other Financial Buyer Transactions Closed

    • Target
    • Buyer
    • Value($mm)
    • Certara, Inc.
    • Arsenal Capital Partners
    • $449.32
    • Etain, LLC
    • RIV Capital Inc. 
    • $246.87
    • Applied Genetic Technologies Corporation
    • Syncona Limited; Syncona Investment Management Limited
    • $93.49

    Other Strategic Buyer Transactions Closed

    • Target
    • Buyer
    • Value($mm)
    • Aerie Pharmaceuticals, Inc.
    • Alcon Research, Ltd.
    • $1,090.84
    • Forma Therapeutics Holdings, Inc.
    • Novo Nordisk A/S
    • $1,060.37
    • Rx Savings, LLC
    • McKesson Corporation
    • $875.00

     

    Source S&P Capital IQ as of 1/9/2023 and PCE Proprietary Data

    New call-to-action

    PCE Transactions

    Contacts

    Michael Poole

    Michael Poole

    Orlando Office

    407-621-2112

    Contact Me Now
    David Jasmund

    David Jasmund

    Orlando Office

    407-621-2111

    Contact Me Now

    Data Assumptions

    This report represents transaction activity as mergers & acquisitions, consolidations, restructurings and spin-offs. Targets are defined as U.S. Based companies with either foreign or U.S. based buyers. Transaction information provided is based on closed dates only.

    Glossary

    EBIT - Earnings Before Interest and Taxes
    EBITDA - Earnings Before Interest, Taxes, Depreciation, Amortization
    LTM - Last Twelve Months
    TEV - Total Enterprise Value

    Sources:

    1. "2022 Year in Review Infographic: Key Investment Banking Trends." S&P Global Market Intelligence, 19 December 2022.
    2. Wainer, David. "Healthcare Deal-Making Set to Surge in 2023." The Wall Street Journal, 27 December 2022.
    3. Shi, Madeline. "PE continues to snatch up healthcare services companies for roll-up plays" Pitchbook, 28 November 2022.
    4. Mensik, Hailey. "Healthcare leaders expect turbulent operating environment next year." Healthcare Dive, 16 December 2022.
    5. "Johnson & Johnson Completes Acquisition of Abiomed." Johnson & Johnson, 22 December 2022.

    Please Share This

    PCE logo

    PCE Investment Bankers, Inc. - member FINRA & SIPC
    PCE Valuations, LLC    |    PCE Advisory, LLC

    SITE MAP

    OFFICES

    [PCE was] completely responsive to our needs and [was] always two steps ahead, leading us expertly through a very complicated process. - Dennis Buhring, Physician Associates

    Copyright © 2023 PCE Companies | Business Continuity | Privacy Policy | FINRA BrokerCheck | Whitelist PCE